Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.50 |
| ▸ | HPGD | P15428 | 4/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | ACHE | P22303 | 3/20 | 0.50 |
| ▸ | GLA | P06280 | 2/20 | 0.50 |
| ▸ | CASP1 | P29466 | 2/20 | 0.50 |
| ▸ | CASP7 | P55210 | 2/20 | 0.50 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.50 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.50 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.50 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.50 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.50 |
| ▸ | NQO2 | P16083 | 1/20 | 0.50 |
| ▸ | MAOA | P21397 | 1/20 | 0.50 |
| ▸ | DRD1 | P21728 | 1/20 | 0.50 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4733753 | 0.79 | NCF1 (0.50) | KDM4EALDH1A1HSD17B10HPGDSMN1; SMN2 | |
| SCHEMBL203711 | 0.78 | LMNA (0.55) | KDM4EALDH1A1HSD17B10HPGDSMN1; SMN2 | |
| SCHEMBL3156746 | 0.78 | CCR1 (0.52) | KDM4ETSHRGPR3BACE1CYP1A2 | |
| SCHEMBL29742219 | 0.78 | LMNA (0.55) | KDM4EALDH1A1HSD17B10HPGDSMN1; SMN2 | |
| SCHEMBL29661797 | 0.78 | CCR1 (0.52) | KDM4ETSHRGPR3BACE1CYP1A2 | |
| Ammonia Solution, Strong SCHEMBL6035045 | 0.77 | LMNA (0.53) | KDM4EALDH1A1HSD17B10HPGDSMN1; SMN2 | |
| SCHEMBL23736298 | 0.76 | PDPK1 (0.42) | KDM4EALDH1A1ACHECASP1CHRM2 | |
| SCHEMBL12210442 | 0.76 | ACHE (0.49) | KDM4EALDH1A1HSD17B10HPGDSMN1; SMN2 | |
| SCHEMBL23474020 | 0.75 | GPR3 (0.52) | KDM4ESMN1; SMN2RAB9AGPR3BACE1 | |
| SCHEMBL23234986 | 0.75 | KDM4E (0.50) | KDM4EALDH1A1HSD17B10HPGDSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE49481-E1 | Compounds for the treatment and prophylaxis of respiratory syncytial virus disease | HOFFMANN-LA ROCHE INC. (US) | 2023-04-04 | — | — | US | claimed |
| EP-1066257-A2 | HETEROCYLIC CLASSES OF COMPOUNDS FOR THE MODULATING TYROSINE PROTEIN KINASE | Sugen, Inc. (US) | 2001-01-10 | — | — | EP | claimed |
| WO-1999048868-A9 | HETEROCYCLIC CLASSES OF COMPOUNDS FOR THE MODULATING TYROSINE PROTEIN KINASE | SUGEN INC (US) | 2000-04-20 | — | — | WO | claimed |
| WO-1999048868-A2 | HETEROCYCLIC CLASSES OF COMPOUNDS FOR THE MODULATING TYROSINE PROTEIN KINASE | SUGEN, INC. (US) | 1999-09-30 | — | — | WO | claimed |
| US-RE49481-E1 | Compounds for the treatment and prophylaxis of respiratory syncytial virus disease | HOFFMANN-LA ROCHE INC. (US) | 2023-04-04 | — | — | US | disclosed |
| US-20200246345-A1 | ALDEHYDE CONJUGATES AND USES THEREOF | ALDEYRA THERAPEUTICS, INC. | 2020-08-06 | — | — | US | disclosed |
| CN-105136787-A | Detection reagent for mono-hydroxyphenyl metabolin urine | SHANGHAI FEI JI BIOTECHNOLOGY CO LTD | 2015-12-09 | — | — | CN | disclosed |
| US-20140221455-A1 | DIFFERENTIATION MODULATING AGENTS AND USES THEREFOR | Verva Pharmaceuticals, Inc. (AU) | 2014-08-07 | — | — | US | disclosed |
| US-8481543-B2 | Compounds for treating parasitic disease | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2013-07-09 | — | — | US | disclosed |
| US-20110251209-A1 | COMPOUNDS FOR TREATING PARASITIC DISEASE | OREGON HEALTH & SCIENCE UNIVERSITY | 2011-10-13 | — | — | US | disclosed |
| WO-2010059633-A2 | COMPOUNDS FOR TREATING PARASITIC DISEASE | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2010-05-27 | — | — | WO | disclosed |
| US-20050282733-A1 | Differentiation modulating agents and uses therefor | VERVA PHARMACEUTICALS PTY LTD (AU) | 2005-12-22 | — | — | US | disclosed |
| WO-2005065686-A1 | DIFFERENTIATION MODULATING AGENTS AND USES THEREFOR | ADIPOGEN PHARMACEUTICALS PTY LIMITED (AU) | 2005-07-21 | — | — | WO | disclosed |
| EP-1066257-A2 | HETEROCYLIC CLASSES OF COMPOUNDS FOR THE MODULATING TYROSINE PROTEIN KINASE | Sugen, Inc. (US) | 2001-01-10 | — | — | EP | disclosed |
| WO-1999048868-A9 | HETEROCYCLIC CLASSES OF COMPOUNDS FOR THE MODULATING TYROSINE PROTEIN KINASE | SUGEN INC (US) | 2000-04-20 | — | — | WO | disclosed |
| WO-1999048868-A2 | HETEROCYCLIC CLASSES OF COMPOUNDS FOR THE MODULATING TYROSINE PROTEIN KINASE | SUGEN, INC. (US) | 1999-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200246345-A1 | ALDEHYDE CONJUGATES AND USES THEREOF | ALDH1A2, AOX1, ALDH2 | KDM4E 2179/4885ALDH1A1 5/4885HSD17B10 386/4885 |
| US-20050282733-A1 | Differentiation modulating agents and uses therefor | FGF1, FABP4, FGF2 | KDM4E 2405/4885ALDH1A1 1103/4885HSD17B10 671/4885 |
| US-20110251209-A1 | COMPOUNDS FOR TREATING PARASITIC DISEASE | EPX, CFTR, TERT | KDM4E 1079/4885ALDH1A1 474/4885HSD17B10 962/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.